## 29<sup>th</sup> Early Detection Research Network (EDRN) Steering Committee Meeting March 31, 2015 – April 2, 2015 Emory Conference Center Hotel, Atlanta, Georgia

# Prostate and Genitourinary Cancers Collaborative Group Meeting Tuesday, March 31, 2015 1:30 p.m. – 5:30 p.m. Salon I&II

### Chair:

James Brooks, M.D., Stanford University

### **NCI Program Directors:**

Jacob Kagan, Ph.D., M.Sc. National Cancer Institute Richard Mazurchuk, Ph.D., National Cancer Institute

**Objective:** The discussions will focus on validation trials, some of which are underway and some are currently being developed. This will enable the EDRN to use its CORE funds in a timely manner to support these trials when the new cycle of the EDRN begins. There will be some turnover in the next round, but in the event that a current investigator who is participating in a validation trial is not funded in the next round, CORE funds will be used to support their participation.

NCI is seeking help in forming Implementation Committees that will work on these proposed validation trials to formalize them before the next cycle begins.

## Agenda

	1
1:30 p.m. – 1:35 p.m.	<u>Welcome</u>
	James Brooks, M.D., Stanford University
	Jacob Kagan, Ph.D., M.Sc., National Cancer Institute
1:35 p.m. – 1:50 p.m.	Richard Mazurchuk, Ph.D., National Cancer Institute
	PCA3 Longitudinal Study
	John Wei, M.D., University of Michigan
	Dan Chan, Ph.D., Johns Hopkins University
1:50 p.m. – 2:10 p.m.	Discussion
	Biomarkers and Clinical Parameters Associated with Gleason Score Upgrading
2:10 p.m. – 2:25 p.m.	(Upgrading Reference Set (URS))
	Ian Thompson, M.D., The University of Texas Health Science Center at San Antonio
2:25 p.m. – 2:45 p.m.	Discussion
	A Biopsy-based 17-Gene Genomic Health Prostate Prognostic Score
2:45 p.m. – 3:00 p.m.	Jennifer Cullen, Ph.D., M.P.H., and Shiv Srivastava, Ph.D., Uniformed Services
	University of the Health Sciences/Center for Prostate Disease Research
3:00 p.m. – 3:20 p.m.	Discussion
3:20 p.m. – 3:40 p.m.	Break
3:40 p.m. – 3:55 p.m.	Measurement of Multiple Protein and RNA Biomarkers in Voided Urine
	Alvin Liu, Ph.D., University of Washington
3:55 p.m. – 4:15 p.m.	Discussion
	Summary and General Discussion
4:15 p.m. – 5:30 p.m.	James Brooks, M.D., Stanford University
	Which projects are "shovel ready"?
	Which projects can be completed within a year?
	On what type of Biomarkers should we focus in our Verification/ Validation
	studies? For example,
	<ul> <li>Early detection of aggressive cancers</li> </ul>
	<ul> <li>Progressors vs. non-progressor among patients on active surveillance</li> </ul>
	<ul> <li>Phenotype/genotype of indolent and aggressive cancers</li> </ul>
	<ul> <li>Limiting the number of unnecessary biopsies</li> </ul>
5:30 p.m.	Adjourn